DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc.
Your view on DNAG
Overview
What the company does, where it operates, and who runs it.
About DNAPrint Genomics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jatin Patel
- Headquarters
- 1621 West University Parkway, Sarasota, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jatin Patel
- Headquarters
- 1621 West University Parkway, Sarasota, US
DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services.
It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer's proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents.
The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for DNAPrint Genomics, Inc., and the rating behind it. DNAG last traded at $0.0000; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for DNAPrint Genomics, Inc.. Starting points for DNAPrint Genomics, Inc.: EPS -$0.03, beta 1.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for DNAPrint Genomics, Inc.. DNAPrint Genomics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for DNAPrint Genomics, Inc.. Trailing twelve-month EPS for DNAPrint Genomics, Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for DNAPrint Genomics, Inc.. DNAPrint Genomics, Inc. has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
DNAPrint Genomics, Inc. valued side by side against its closest peers. DNAPrint Genomics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold DNAPrint Genomics, Inc., and how their positions are changing. At a $6,446 market value, institutional positions materially move DNAPrint Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by DNAPrint Genomics, Inc. executives and directors. Shares of DNAPrint Genomics, Inc. have traded between $0.0000 and $0.0000 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming DNAPrint Genomics, Inc.. DNAPrint Genomics, Inc. is a $6,446 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming DNAPrint Genomics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for DNAPrint Genomics, Inc.. Coverage tracks DNAPrint Genomics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.